Application of RUNX3 gene promoter methylation in the diagnosis of non-small cell lung cancer

Yu,Gui-Ping; Ji,Yong; Chen,Guo-Qiang; Huang,Bin; Shen,Kai; Wu,Song; Shen,Zhen-Ya

doi:10.3892/ol.2011.450

Application of RUNX3 gene promoter methylation in the diagnosis of non-small cell lung cancer

Authors:
- Gui-Ping Yu
- Yong Ji
- Guo-Qiang Chen
- Bin Huang
- Kai Shen
- Song Wu
- Zhen-Ya Shen
View Affiliations

Affiliations: Department of Cardiothoracic Surgery, The Affiliated Jangyin People's Hospital of Southeast University Medical College, Jiangyin, Jiangsu 214400, P.R. China
Published online on: October 19, 2011 https://doi.org/10.3892/ol.2011.450
Pages: 159-162

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The purpose of this study was to detect the methy-lation of the RUNX3 gene promoter in non-small cell lung cancer (NSCLC) tissue and to explore the association of this methylation with clinical features of NSCLC. In 58 samples of NSCLC tissue and normal adjacent tissue, methylation of the RUNX3 gene promoter was measured by methylation-specific polymerase chain reaction. Correlation with clinicopathological characteristics was assessed. The results demonstrated that RUNX3 gene promoter methylation was present in 26/58 (44.8%) of NSCLC tissue samples and 10/58 (17.2%) of normal tissue samples, and that the difference was statistically significant between the two groups (χ2=10.311, p=0.001). Significantly, methylation of the RUNX3 gene promoter correlated with clinical stage, lymph node metastasis and the degree of differentiation (p<0.05) but not with age, gender, smoking history and pathological type (p>0.05). In conclusion, methylation of the RUNX3 gene promoter had a high relevance ratio in NSCLC tissue and correlated with clinical stage, lymph node metastasis and degree of differentiation; thus, this association may have clinical significance in NSCLC.

View Figures

View References

1	Kim JS, Kim JW, Han J, Shim YM, Park J and Kim DH: Cohypermethylation of p16 and FHIT promoters as a prognostic factor of recurrence in surgically resected stage I non-small cell lung cancer. Cancer Res. 66:4049–4054. 2006. View Article : Google Scholar : PubMed/NCBI
2	Esteller M: Epigenetics provides a new generation of oncogenes and tumour-suppressor genes. Br J Cancer. 94:179–183. 2006. View Article : Google Scholar : PubMed/NCBI
3	Yamada Y, Jackson-Grusby L, Linhart H, Meissner A, Eden A, Lin H and Jaenisch R: Opposing effects of DNA hypomethylation on intestinal and liver carcinogenesis. Proc Natl Acad Sci USA. 102:13580–13585. 2005. View Article : Google Scholar : PubMed/NCBI
4	Carraway H and Herman J: Montoring methylation changes in caner. Methods Mol Biol. 383:187–202. 2007.
5	Chim CS, Liang R, Leung MH and Kwong YL: Aberrant gene methylation implicated in the progression of monoclonal gammopathy of undetermined significance to multiple myeloma. J Clin Pathol. 60:104–106. 2007. View Article : Google Scholar : PubMed/NCBI
6	Durst KL and Hiebert SW: Role of RUNX family members in transcriptional repression and gene silencing. Oncogene. 23:4220–4224. 2004. View Article : Google Scholar : PubMed/NCBI
7	Levanon D, Negreanu V, Bernstein Y, Bar-Am I, Avivi L and Groner Y: AML1, AML2, and AML3, the human members of the runt domain gene-family: cDNA structure, expression, and chromosomal localization. Genomics. 23:425–432. 1994. View Article : Google Scholar : PubMed/NCBI
8	Ito Y: Molecular basis of tissue-specific gene expression mediated by the runt domain transcription factor PEBP2/CBF. Genes Cells. 4:685–696. 1999. View Article : Google Scholar : PubMed/NCBI
9	Bae SC and Choi JK: Tumor suppressor activity of RUNX3. Oncogene. 23:4336–4340. 2004. View Article : Google Scholar : PubMed/NCBI
10	Miyazono K, Suzuki H and Imamura T: Regulation of TGF-beta signaling and its roles in progression of tumors. Cancer Sci. 94:230–234. 2003. View Article : Google Scholar : PubMed/NCBI
11	Blyth K, Cameron ER and Neil JC: The RUNX genes: gain or loss of function in cancer. Nat Rev Cancer. 5:376–387. 2005. View Article : Google Scholar : PubMed/NCBI
12	Jiang Y, Tong D, Lou G, Zhang Y and Geng J: Expression of RUNX3 gene, methylation status and clinicopathological significance in breast cancer and breast cancer cell lines. Pathobiology. 75:244–251. 2008. View Article : Google Scholar : PubMed/NCBI
13	Kim EJ, Kim YJ, Jeong P, Ha YS, Bae SC and Kim WJ: Methylation of the RUNX3 promoter as a potential prognostic marker for bladder tumor. J Urol. 180:1141–1145. 2008. View Article : Google Scholar : PubMed/NCBI
14	Nomoto S, Kinoshita T, Mori T, Kato K, Sugimoto H, Kanazumi N, Takeda S and Nakao A: Adverse prognosis of epigenetic inactivation in RUNX3 gene at 1p36 in human pancreatic cancer. Br J Cancer. 98:1690–1695. 2008. View Article : Google Scholar : PubMed/NCBI
15	Waki T, Tamura G, Sato M, Terashima M, Nishizuka S and Motoyama T: Promoter methylation status of DAP-kinase and RUNX3 genes in neoplastic and non-neoplastic gastric epithelia. Cancer Sci. 94:360–364. 2003. View Article : Google Scholar : PubMed/NCBI
16	Friedrich MJ, Rad R, Langer R, Voland P, Hoefler H, Schmid RM, Prinz C and Gerhard M: Lack of RUNX3 regulation in human gastric cancer. J Pathol. 210:141–146. 2006. View Article : Google Scholar : PubMed/NCBI
17	Tan SH, Ida H, Lau QC, Goh BC, Chieng WS, Loh M and Ito Y: Detection of promoter hypermethylation in serum samples of cancer patients by methylation-specific polymerase chain reaction for tumour suppressor genes including RUNX3. Oncol Rep. 18:1225–1230. 2007.
18	Sato K, Tomizawa Y, Iijima H, Saito R, Ishizuka T, Nakajima T and Mori M: Epigenetic inactivation of the RUNX3 gene in lung cancer. Oncol Rep. 15:129–135. 2006.
19	Yanagawa N, Tamura G, Oizumi H, Kanauchi N, Endoh M, Sadahiro M and Motoyama T: Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers. Lung Cancer. 5:131–138. 2007. View Article : Google Scholar : PubMed/NCBI
20	Yanagawa N, Tamura G, Oizumi H, et al: Promoter hypermethylation of tumor suppressor and tumor-related genes in non-small cell lung cancers. Cancer Sci. 94:589–592. 2003. View Article : Google Scholar : PubMed/NCBI
21	Li QL, Kim HR, Kim WJ, Choi JK, Lee YH, Kim HM, Li LS, Kim H, Chang J, Ito Y, Youl Lee K and Bae SC: Transcriptional silencing of the RUNX3 gene by CpG hypermethylation is associated with lung cancer. Biochem Biophys Res Commun. 314:223–228. 2004. View Article : Google Scholar : PubMed/NCBI
22	Herranz M and Esteller M: DNA methylation and histone modifications in patients with cancer: potential prognostic and therapeutic targets. Methods Mol Biol. 361:25–62. 2007.PubMed/NCBI
23	Fojtova M, Piskala A, Votruba I, Otmar M, Bartova E and Kovarik A: Efficacy of DNA hypomethylating capacities of 5-aza-2′-deoxycytidine and its alpha anomer. Pharmacol Res. 55:16–22. 2007.PubMed/NCBI